A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis

Exclusion Criteria12

• Any of the following forms of IC: including osteomyelitis, endocarditis or myocarditis, meningitis, endophthalmitis, or any central nervous system infection, urinary tract infection or chronic disseminated candidiasis；
• Severe hepatic impairment in subjects with a history of chronic cirrhosis；
• History of severe ataxia, tremor, or neuropathy or a diagnosis of multiple sclerosis or a movement;
• Laboratory abnormalities in baseline specimens obtained at screening;
• ECG with clinical significance and may cause obvious safety risk to the subjects at screening;
• Received systemic treatment with an antifungal agent at approved doses for treatment of candidemia or IC for >48 hours;
• Vascular catheter or device that cannot be removed, or abscess that cannot be drained, and may be the source of candidemia or IC;
• A history of drug use, alcohol, or drug abuse within 1 year prior to randomization;
• Participated in, any other clinical study involving the administration of active investigational or experimental medication prior to the randomization, or 5 half-lives, whichever is longer, prior to Screening;
• Females who are in gestation or lactating period or planned pregnancy during the study
• Known history of hypersensitivity or allergic reaction to HRS9432, caspofungin etc echinocandins drugs;
• In the judgment of the Investigator, other reasons unsuitable for study.